183 related articles for article (PubMed ID: 29296538)
1. Phase I study of glypican-3-derived peptide vaccine therapy for patients with refractory pediatric solid tumors.
Tsuchiya N; Hosono A; Yoshikawa T; Shoda K; Nosaka K; Shimomura M; Hara J; Nitani C; Manabe A; Yoshihara H; Hosoya Y; Kaneda H; Kinoshita Y; Kohashi K; Yoshimura K; Fujinami N; Saito K; Mizuno S; Nakatsura T
Oncoimmunology; 2017; 7(1):e1377872. PubMed ID: 29296538
[TBL] [Abstract][Full Text] [Related]
2. Phase I trial of a glypican-3-derived peptide vaccine for advanced hepatocellular carcinoma: immunologic evidence and potential for improving overall survival.
Sawada Y; Yoshikawa T; Nobuoka D; Shirakawa H; Kuronuma T; Motomura Y; Mizuno S; Ishii H; Nakachi K; Konishi M; Nakagohri T; Takahashi S; Gotohda N; Takayama T; Yamao K; Uesaka K; Furuse J; Kinoshita T; Nakatsura T
Clin Cancer Res; 2012 Jul; 18(13):3686-96. PubMed ID: 22577059
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of the NCCV Cocktail-1 vaccine for refractory pediatric solid tumors: A phase I clinical trial.
Akazawa Y; Hosono A; Yoshikawa T; Kaneda H; Nitani C; Hara J; Kinoshita Y; Kohashi K; Manabe A; Fukutani M; Wakabayashi M; Sato A; Shoda K; Shimomura M; Mizuno S; Nakamoto Y; Nakatsura T
Cancer Sci; 2019 Dec; 110(12):3650-3662. PubMed ID: 31571332
[TBL] [Abstract][Full Text] [Related]
4. HLA-A2-restricted glypican-3 peptide-specific CTL clones induced by peptide vaccine show high avidity and antigen-specific killing activity against tumor cells.
Yoshikawa T; Nakatsugawa M; Suzuki S; Shirakawa H; Nobuoka D; Sakemura N; Motomura Y; Tanaka Y; Hayashi S; Nakatsura T
Cancer Sci; 2011 May; 102(5):918-25. PubMed ID: 21281401
[TBL] [Abstract][Full Text] [Related]
5. Immunological efficacy of glypican-3 peptide vaccine in patients with advanced hepatocellular carcinoma.
Tsuchiya N; Yoshikawa T; Fujinami N; Saito K; Mizuno S; Sawada Y; Endo I; Nakatsura T
Oncoimmunology; 2017; 6(10):e1346764. PubMed ID: 29123959
[TBL] [Abstract][Full Text] [Related]
6. [Cancer peptide vaccine targeted glypican-3 antigen].
Nakatsura T
Nihon Rinsho; 2017 Feb; 75(2):257-262. PubMed ID: 30562861
[TBL] [Abstract][Full Text] [Related]
7. Significant clinical response of progressive recurrent ovarian clear cell carcinoma to glypican-3-derived peptide vaccine therapy: two case reports.
Suzuki S; Shibata K; Kikkawa F; Nakatsura T
Hum Vaccin Immunother; 2014; 10(2):338-43. PubMed ID: 24252799
[TBL] [Abstract][Full Text] [Related]
8. Vaccination with liposome-coupled glypican-3-derived epitope peptide stimulates cytotoxic T lymphocytes and inhibits GPC3-expressing tumor growth in mice.
Iwama T; Uchida T; Sawada Y; Tsuchiya N; Sugai S; Fujinami N; Shimomura M; Yoshikawa T; Zhang R; Uemura Y; Nakatsura T
Biochem Biophys Res Commun; 2016 Jan; 469(1):138-143. PubMed ID: 26616051
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of glypican-3-derived peptide vaccine therapy on the survival of patients with refractory ovarian clear cell carcinoma.
Suzuki S; Sakata J; Utsumi F; Sekiya R; Kajiyama H; Shibata K; Kikkawa F; Nakatsura T
Oncoimmunology; 2016; 5(11):e1238542. PubMed ID: 27999758
[TBL] [Abstract][Full Text] [Related]
10. Peptide vaccine as an adjuvant therapy for glypican-3-positive hepatocellular carcinoma induces peptide-specific CTLs and improves long prognosis.
Taniguchi M; Mizuno S; Yoshikawa T; Fujinami N; Sugimoto M; Kobayashi S; Takahashi S; Konishi M; Gotohda N; Nakatsura T
Cancer Sci; 2020 Aug; 111(8):2747-2759. PubMed ID: 32449239
[TBL] [Abstract][Full Text] [Related]
11. [The cancer specific antigen, glypican-3 (GPC3)-targeted immunotherapy].
Sawada Y; Nakatsura T
Nihon Rinsho; 2012 Dec; 70(12):2136-41. PubMed ID: 23259386
[TBL] [Abstract][Full Text] [Related]
12. Analysis of cytotoxic T lymphocytes from a patient with hepatocellular carcinoma who showed a clinical response to vaccination with a glypican‑3‑derived peptide.
Tada Y; Yoshikawa T; Shimomura M; Sawada Y; Sakai M; Shirakawa H; Nobuoka D; Nakatsura T
Int J Oncol; 2013 Oct; 43(4):1019-26. PubMed ID: 23903757
[TBL] [Abstract][Full Text] [Related]
13. Remarkable tumor lysis in a hepatocellular carcinoma patient immediately following glypican-3-derived peptide vaccination: an autopsy case.
Sawada Y; Yoshikawa T; Fujii S; Mitsunaga S; Nobuoka D; Mizuno S; Takahashi M; Yamauchi C; Endo I; Nakatsura T
Hum Vaccin Immunother; 2013 Jun; 9(6):1228-33. PubMed ID: 23466818
[TBL] [Abstract][Full Text] [Related]
14. Phase II study of the GPC3-derived peptide vaccine as an adjuvant therapy for hepatocellular carcinoma patients.
Sawada Y; Yoshikawa T; Ofuji K; Yoshimura M; Tsuchiya N; Takahashi M; Nobuoka D; Gotohda N; Takahashi S; Kato Y; Konishi M; Kinoshita T; Ikeda M; Nakachi K; Yamazaki N; Mizuno S; Takayama T; Yamao K; Uesaka K; Furuse J; Endo I; Nakatsura T
Oncoimmunology; 2016 May; 5(5):e1129483. PubMed ID: 27467945
[TBL] [Abstract][Full Text] [Related]
15. Glypican-3 could be an effective target for immunotherapy combined with chemotherapy against ovarian clear cell carcinoma.
Suzuki S; Yoshikawa T; Hirosawa T; Shibata K; Kikkawa F; Akatsuka Y; Nakatsura T
Cancer Sci; 2011 Sep; 102(9):1622-9. PubMed ID: 21668581
[TBL] [Abstract][Full Text] [Related]
16. Glypican-3-specific cytotoxic T lymphocytes induced by human leucocyte antigen-A*0201-restricted peptide effectively kill hepatocellular carcinoma cells in vitro.
Zeng JZ; Liu Y; Huang F; He ZH; Sun H; Lu YD; Lei JH; Luo RC
Asian Pac J Trop Med; 2017 Nov; 10(11):1084-1089. PubMed ID: 29203107
[TBL] [Abstract][Full Text] [Related]
17. Glypican 3 expression in pediatric malignant solid tumors.
Kinoshita Y; Tanaka S; Souzaki R; Miyoshi K; Kohashi K; Oda Y; Nakatsura T; Taguchi T
Eur J Pediatr Surg; 2015 Feb; 25(1):138-44. PubMed ID: 25344940
[TBL] [Abstract][Full Text] [Related]
18. Radiofrequency ablation for hepatocellular carcinoma induces glypican-3 peptide-specific cytotoxic T lymphocytes.
Nobuoka D; Motomura Y; Shirakawa H; Yoshikawa T; Kuronuma T; Takahashi M; Nakachi K; Ishii H; Furuse J; Gotohda N; Takahashi S; Nakagohri T; Konishi M; Kinoshita T; Komori H; Baba H; Fujiwara T; Nakatsura T
Int J Oncol; 2012 Jan; 40(1):63-70. PubMed ID: 21922136
[TBL] [Abstract][Full Text] [Related]
19. Identification of glypican-3-derived long peptides activating both CD8
Sayem MA; Tomita Y; Yuno A; Hirayama M; Irie A; Tsukamoto H; Senju S; Yuba E; Yoshikawa T; Kono K; Nakatsura T; Nishimura Y
Oncoimmunology; 2016; 5(1):e1062209. PubMed ID: 26942076
[TBL] [Abstract][Full Text] [Related]
20. Immunotherapeutic Targeting of GPC3 in Pediatric Solid Embryonal Tumors.
Ortiz MV; Roberts SS; Glade Bender J; Shukla N; Wexler LH
Front Oncol; 2019; 9():108. PubMed ID: 30873384
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
